再造丸联合放疗治疗晚期非小细胞肺癌脑转移临床观察  

Clinical study on brain metastases of late stage non-small cell lung cancer treated with Zaizao pill combined with radiotherapy

作　　者：方庆亮 王蕾[1] 刘雪 顾煜恺 顾香莲 鹿振辉[1] FANG Qingliang;WANG Lei;LIU Xue;GU Yukai;GU Xianglian;LU Zhenhui(Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院,上海200032

出　　处：《陕西中医》2024年第12期1625-1629,共5页Shaanxi Journal of Traditional Chinese Medicine

基　　金：上海市科技计划项目(21Y11922400);“龙医科技创新培育计划”临床医学引导项目(YD202204)。

摘　　要：目的:探讨再造丸联合放疗治疗晚期非小细胞肺癌脑转移的临床疗效。方法:选择晚期非小细胞肺癌脑转移患者78例,采取简单化分组方法分为两组,各39例,对照组给予放疗,观察组在其基础上给予再造丸治疗,观察两组患者治疗前后生存周期[中位无进展生存期(PFS)、中位总生存时间(OS)]、中医证候评分、中医证候疗效评价、血清肿瘤因子[血清癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)]、肺癌患者生活质量量表(EORTC QLQ-LC43)评分及不良反应。结果:治疗后两组中医证候评分、血清肿瘤因子水平较治疗前降低,且观察组低于对照组(均P<0.05)。治疗后观察组中医证候总有效率为89.74%显著高于对照组的71.79%(P<0.05)。治疗后两组情感功能、社会功能、生理功能、角色功能、认知功能、总健康状况评分较治疗前升高,且观察组高于对照组(均P<0.05)。观察组生存周期长于对照组(P<0.05)。治疗期间两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:再造丸联合放疗可有效提高晚期非小细胞肺癌脑转移患者生存周期及生活质量。Objective:To observe the Zaizao pill combined with chemotherapy in the treat of NSCLC with brain metastases.Methods:A total of 78 patients with NSCLC with brain metastases were divided into two group.The contrast group was given radiotherapy,and the observe group was given Zaizao pill on the basis of the contrast group.The survival cycle[median progression-free survival(PFS),median overall survival(OS)],TCM syndrome score,TCM syndrome efficacy evaluation,serum tumor factors[serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 125(CA125)],EORTC QLQ-LC43 score and adverse reactions of the two groups before and after treatment were observed.Results:After treatment,TCM syndrome score and serum tumor factor levels of the observe group were lower than before treatment and contrast group(all P<0.05).Total effective rate of the TCM syndromes in observe group was higher than control group(P<0.05).After treatment,the EORTC QLQ-LC43 scores in observe group were higher than before treatment and contrast group(all P<0.05),and survival cycle in observe group higher than contrast group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Zaizao pill combined with chemotherapy can effectively improve the survival cycle and quality of life of advanced non-small cell lung cancer patients with brain metastases.

关 键 词：非小细胞肺癌 再造丸 放疗 脑转移 生存周期 肿瘤因子 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]